PacBio announces innovations to Revio and Vega genome platforms

PacBio (PACB) announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The advancements center on new SPRQ-Nx sequencing chemistry and consumables, designed to deliver PacBio’s most affordable HiFi genome to date. Customers operating at scale could see as much as a 40% reduction from current costs, down to a price of less than $300 per genome. Additional improvements include 5hmC detection for epigenetic profiling and 21 CFR Part 11 compliance features for Vega. Beta testing of SPRQ-Nx chemistry on the higher throughput Revio is expected to begin in November 2025, with full commercial availability planned in 2026. PacBio intends to achieve these cost savings by enabling multiple runs per SMRT Cell while maintaining output per run. Vega, PacBio’s benchtop system, will integrate SPRQ-Nx chemistry and 5hmC detection capabilities in 2026. These upgrades will include secure authentication and audit logging features to support 21 CFR Part 11 compliance for labs operating under regulated conditions.